Tilmanocept for Cardiac Sarcoidosis Imaging
This study is looking into whether a special imaging technique using Tc 99m tilmanocept can help identify cardiac sarcoidosis, a condition where inflammatory cells grow in the heart. Researchers will give participants Tc 99m tilmanocept either through an IV (into a vein) or SC (under the skin) injection, followed by a SPECT-CT scan. The main goal is to see if the areas of the heart that show uptake of tilmanocept match the areas that show uptake of another imaging agent called fluorodeoxyglucose (FDG) on a different type of scan (PET-CT). This study plans to enroll 15 participants who are at least 18 years old. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 15 participants. It is designed to compare imaging results from two different ways of giving Tc 99m tilmanocept.
- What's involved
- You would receive an injection of Tc 99m tilmanocept (either IV or under the skin) and then have a SPECT-CT imaging scan. The primary endpoint is measured at the time of the scan (Baseline).
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at the time of the scan (Baseline).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Repurposing Tilmanocept for Cardiac Sarcoidosis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ravi Karra, MD · PRINCIPAL_INVESTIGATOR · Duke Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Correlation between the cardiac segments with tilmanocept uptake and the cardiac segments with fluorodeoxyglucose (FDG) uptake on cardiac PET-CT. For each imaging modality, a standard 17-segment cardiac model will be used.At the time of the scan (Baseline)